Our partners

Our partners' expertise and engagement are fundamental to drive long-term and measurable changes in cancer control.

a woman and a man shaking hands at 2019 World Cancer Leaders Summit in Kazakhstan

Click on the logos here below to see more information about each partner.

Patrons Programme

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.

Founded in 1951 to support cancer research, the Swedish Cancer Society is an independent non-profit organization with the vision of finding cures for cancer. The overall aim of the Society is to achieve a higher survival rate and a reduction in the incidence of cancer. Their main task is to raise and distribute money for cancer research. As one of the largest financiers of cancer research in Sweden, the Swedish Cancer Society essentially acts as a national research council. Thanks to the organization’s extensive knowledge about cancer, the Swedish Cancer Society is also active in areas such as public opinion and spreading knowledge about cancer, as well as results of cancer research.

Danish Cancer Society aims to prevent the development of cancer, to improve patients' chances of successful recovery, to limit the physical, psychological and social side-effects of cancer.

The group`s main activities are within research, patient support and prevention. The society has recently begun to focus on wellness programs like: health, food, and biotech advances.

The Dutch Cancer Society is a nation-wide organization for cancer control in the Netherlands. The society was funded in 1949 by Queen Wilhelmina. Her granddaughter, Her Royal Highness Princess Beatrix, is the current patron. The Dutch Cancer Society’s ideal world is one in which nobody dies from cancer ever again. We want fewer people to get cancer, more people to cure, and patients to have a better quality of life, during and after the disease. That’s why we fund and facilitate scientific research, influence policy, and share our knowledge about cancer and its treatment. To make this possible, we raise funds and establish links with other parties involved in cancer control, both here in the Netherlands and elsewhere. The Dutch Cancer Society is entirely dependent on community involvement and donations. Over 100.000 volunteers support the Dutch Cancer Society whether it comes to local or nation-wide fundraising, scientific or policy advice in several councils and committees. We can rely on nearly 1.500 local committees that organize fundraising activities e.g. our annual door-to-door campaign to raise funds for the fight against cancer. The Dutch Cancer Society is supported by over 1 million donors. The Dutch Cancer Society’s office is located in Amsterdam; our professional staff amounts to 198 staff members.

N°1 dermatologist recommended skincare brand worldwide, La Roche-Posay’s mission is to offer life-changing dermatological skincare solutions. Recommended by 90,000 dermatologists worldwide*, La Roche-Posay was created by a pharmacist in 1975. The brand is today present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their dermatological treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water, also used at its Thermal Center, the first Dermatology Center in Europe, due to its antioxidant and soothing properties. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin.  The La Roche-Posay Cancer Support program includes two pillars related to the fight against cancer: Fight With Care to improve patients’ quality of life during all cancer treatment for better adherence and higher chances of healing, and Save Your Skin to prevent skin cancer specifically. On both topics, the brand is committed to raising awareness, training health care professional and the general public, and helping patients by supporting NGOs’ projects beyond skincare. Since 2019, the Fondation La Roche-Posay is also committed to improving the life of children with cancer and their families. In 2020, the brand went a step further in its commitment to protect the planet. Besides launching the first eco-designed tubes integrating cardboard, the brand announced a long-term plan to reduce its use of virgin plastic by 70% in 2025.

For additional information about La Roche-Posay, visit www.laroche-posay.com.

*source: survey on the dermocosmetic market carried out by iqvia and other partners (ipsos, tns) between september 2017 and august 2018 among dermatologists in 62 countries.

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.

Champions programme


The Asociación Española Contra el Cáncer (AECC) (Spanish Association Against Cancer) is a non-profit, private social entity which has been declared of public utility. It was founded in 1953. The mission of the AECC is the fight against cancer leading the efforts of the Spanish society to decrease the impact of this disease and to improve the people’s quality of life. Four main strategic pillars guide the activities of the association: information & awareness, cancer patients support, research, and advocacy & lobbying. It is a nation wide organisation with 52 provincial delegations and more than 2.000 local delegations. The association counts on more than 109.000 members, 14.000 volunteers and 730 workers to develop its activities. In 1971, the AECC established its Scientific Foundation which main purpose is to improve cancer research in Spain. The Asociacion Española Contra el Cancer became a full UICC member in 1962.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.  

Becton, Dickinson and Company (BD) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. They provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, their company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.

Through the outstanding knowledge and commitment of their 15,000 employees worldwide, they create innovative new and generic medicines, and new methods of drug discovery and delivery. Daiichi Sankyo share a passion for innovation, as well as compassion for the patients around the world who are in need of their medicines.

An umbrella foundation associated with the bank Lombard Odier and a registered charity, Fondation Philanthropia has been helping its donors bring their philanthropic initiatives to fruition in all areas of social responsibility since 2008. It provides philanthropic expertise and support to those who wish to develop a philanthropic project in line with their background, desires and ambitions. The Foundation offers its donors a legal, financial and philanthropic framework for made-to-measure projects.

The Foundation now operates more than 20 personal funds and has received over 115 million Swiss francs in donations, of which over a third has already been distributed or committed. Its donors have been highly committed to the fight against cancer, with over 15 million spent on the cause.

Hologic, Inc. is a global medical technology innovator primarily focused on improving women’s health and well-being through early detection and treatment. Its advancements include leadership in providing diagnostic solutions for cervical cancer screening, sexually transmitted infections, respiratory illnesses, and the virus that causes COVID-19; invention of the world’s first commercial 3D mammography system to fight breast cancer; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding. The company champions women through the Hologic Global Women’s Health Index, which provides a science-backed data roadmap for improving women’s well-being, and Project Health Equality, which elevates awareness, research insights and access to quality care for underserved women.

The French National Cancer Institute (INCa) was established under the French Public Health Act of August 9, 2004, as the State health and science agency specialised in cancer control. The Institute operates under the supervision of the French Ministry of Health and Solidarities and the French Ministry of Higher Education, Research and Innovation. It provides an integrated approach encompassing all cancer-control aspects (health, scientific, social and economic) and intervention areas (prevention, screening, care, research) to benefit patients and their relatives. The Institute is also a trusted source of evidence-based information, providing reliable advice on cancer control to government and guidance to health professionals and the community. The Institute drives the implementation of the French decennial strategy against cancer (2021-2030): it plays a pivotal role in maximising coordination amongst cancer control stakeholders to enhance impact.

‘You have cancer.’ More than 40,000 Flemish people are given this diagnosis every year. 1 in 4 women develop the disease before the age of 75. In men it is even 1 in 3. Fortunately, survival rates are up. This means increasingly more people live with the consequences of cancer. In Flanders more than a quarter of a million already. Kom op tegen Kanker (Stand up to Cancer), an independent ngo and non-profit organisation, plays a leading role in this and is the point of contact in the fight against cancer in Flanders and Brussels. Our dream? A world in which we no longer lose loved ones to cancer. But we're not there yet. We will fight until this dream becomes reality. How? By preventing and fighting cancer. But also by alleviating the effects of cancer and advocating a better cancer policy. To be able to do this, we mobilise as many people as possible to fight against cancer: as care volunteer, campaigner or donor.  Find out more about our organisation and how you can help on komoptegenkanker.be.  

The Swiss Cancer League is a national, charitable, private organisation, founded in 1910. It is the Berne-based headquarter of an association of 19 regional cancer leagues. The Swiss Cancer League covers all aspects of cancer, with the aim of ensuring that fewer people develop cancer, fewer people suffer and die from the consequences of cancer and more people can be treated successfully. The organisation supports innovative cancer research projects, increases public awareness of prevention measures and is committed to early diagnosis and treatment. One of its first concerns is to ensure high-quality advice and psychological support for all cancer patients and survivors and their caretakers. The Swiss Cancer League also supports other cancer control organisations in low income countries.

The Japan National Committee for UICC is a group of Japanese organisations that are members of the Union for International Cancer Control (UICC), gathered to support the UICC to strive to realise the World Cancer Declaration. Currently UICC-Japan is composed of 29 full Japanese UICC members, including major cancer specialists in Japan, cancer centres, research institutes, research funds, hospitals and cancer associations.



AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, BeiGene is expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030.

Through scientific innovation and collaboration, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments for patients in areas of high unmet medical need. Their oncology research is driven by a passion to improve the lives of patients who are battling cancer and a determination for cancer to eventually be treated as a chronic condition. They seek out strong partnerships and remain dedicated to expanding our portfolio of treatments in both solid tumours and haematological cancers. Boehringer Ingelheim prides in their unique approach to research and discovery which is currently focused on angiogenesis inhibition, signal transduction inhibition, cell-cycle kinase inhibition, immunotherapy, apoptosis, epigenetics and protein homeostasis.

The Canadian Partnership Against Cancer is an independent organisation funded by the federal government to accelerate action on cancer control for all Canadians. The Partnership works with cancer experts, charitable organisations, governments, cancer agencies, national health organisations, patients, survivors and others to achieve their shared goal of a future in which fewer Canadians get cancer, fewer die from it and those living with the disease have a better quality of life. The Partnership’s work spans the cancer control continuum, from prevention and screening to research and supportive care. Their collaborative approach is mindful of the patient voice, and strives to be culturally responsive to the needs of local communities.

Cancer Council is Australia’s leading cancer charity working across every aspect of every cancer.  Every day, Cancer Council supports families affected by cancer when they need it most, works with the community to change laws and policies to reduce cancer risks and improve cancer care, empowers Australians to reduce their cancer risk, and funds more world-class cancer research than any other-non government organisation in Australia to reduce the impact of cancer.  Thanks to the support of the Australian public, Cancer Council is getting closer to a cancer free future every minute, every hour, every day.

Founded in 1936, the Cancer Society of Finland is the largest patient and public health organisation in Finland as well as being an expert organisation nationally. The aim of CSF is to prevent cancer, promote health and ensure a good quality of life for people with cancer. The CSF comprises of 12 regional cancer societies and six national patient organisations. The CSF’s member societies are independent actors that adhere to commonly agreed values and working principles. Activities are based on the results of scientific research, which is funded through grants offered by the Cancer Foundation Finland sr and the Foundation for the Finnish Cancer Institute sr. The Finnish Cancer Registry is a statistical and epidemiological cancer research institute that has run a database of all cases of cancer in Finland since 1952.

Curium is the world’s largest nuclear medicine company following the union of two  major North American and European suppliers. We develop, manufacture and distribute  world-class radiopharmaceutical products to help patients around the globe. Our proven  heritage combined with a pioneering approach are the hallmarks to deliver innovation,  excellence and unparalleled service. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie,  after whom the radioactive element curium was named. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team. Since our formation in 2017, we are pleased to report solid financial performance, which in turn supports significant investments to accelerate our growth through new product development and acquisitions. By reinvesting back into our business and products, we remain firmly focused on delivering vital products to over 35,000 patients who are in need of crucial diagnosis and treatment every day. In 2018, Curium became the first to offer 100% LEU generators in North America and has since expanded to supply LEU generators globally. We recently secured a contract supporting Curium’s long term molybdenum production. Through acquisition, we expanded our Positron Emission Tomography (PET) network to 26 sites world-wide, executed agreements for the development and distribution of new PET diagnostic agents and added new products to our portfolio. Another key achievement was our CEO, Renaud Dehareng, receiving prestigious recognition as one of USA’s top CEOs in 2017 and winning CEO Healthcare Award in 2018.

Icon Group is a leading provider of cancer care across Australasia. Icon believes in bringing the best cancer treatment possible, to as many people as possible, as close to home as possible. They do this through leveraging the latest technology, collaborating with like-minded partners and investing in outstanding people.

The McKinsey Cancer Center (McKCC) combines the extensive cross-functional oncology experience of our team with methodologies for generating deep market insights, advanced-analytics platforms, and input from a network of leading external experts. We work to advance cutting-edge oncology innovations (both therapeutic and diagnostic) with pharmaceutical and biotech companies and investors. Approaches we design make it possible for health-care providers to deliver better care, and solutions we propose help health systems and policy makers realize the best possible outcomes for cancer patients. Operating in all geographies, the McKinsey Cancer Center conducts more than 100 client engagements annually across strategy, R&D, business development, marketing and sales, market access and policy, and care-delivery topics. We share our cutting-edge knowledge at international oncology conferences, as well as in peer-reviewed publications and other leading industry journals.

National Cancer Centre (NCC) was established in 2000. It strives to improve national health and welfare by reducing the incidence and mortality of cancer through research, patient care, education & training, and support for the national cancer control programs. "Vision 2020" is a program that represents the organizations goals into the future, where it fights to protect the Korean people from cancer through innovative research, quality medical care, optimal training of cancer experts, and support for national cancer control programs. 

NCS is an active civil society actor which contributes to targeted efforts in cancer information, prevention, advocacy, research, care, and international cooperation. Their activities are funded thanks to the contributions of its members, bequests, and allocations from the national lottery funds. Their main objectives are to: Contribute to ensure that fewer people develop cancer (reduction of the prevalence and incidence of cancer), Contribute to more people surviving cancer, Ensure the best quality of life for people affected by cancer (cancer patients and their relatives). The vision of NCS is: “Together we create hope”.

The mission of the Prevent Cancer Foundation® is saving lives across all populations through cancer prevention and early detection. The Prevent Cancer Foundation® is one of the leading voluntary health organizations in the U.S. and the only U.S. non-profit focused solely on cancer prevention and early detection. Founded in 1985, it has catapulted cancer prevention to prominence and fulfils its mission through research, education, outreach and advocacy. The Foundation’s vision is to Stop Cancer Before It Starts!®

Sylvester comprehensive cancer center supports research and outreach in the cancer prevention, early detection, and survivorship. Such efforts primarily target culturally-diverse communities throughout South Florida, including those characterized by health disparity and lack of access to the formal healthcare system. Much of our work is grounded in the principles of stakeholder engagement, where patients, religious leaders, and community activists work collaboratively with our scientists and clinicians to ensure that our cancer control initiatives match community need.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion.

Economist Events brings the rigour of informed analysis and intelligent debate that The Economist is known for to life on stage in international forums. We host over 80 events annually in over 30 countries on topics that convene world-class thought leaders on a range of strategic business issues.

The world-leading journal dedicated to clinical oncology research

The Lancet Oncology covers topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology. Topics include but are not limited to breast cancer; endocrine system cancer; gastrointestinal cancer; genitourinary cancer; gynaecological cancer; haematological cancer; head and neck cancer; neurooncology; paediatric oncology; thoracic oncology; sarcoma; skin cancer; epidemiology, cancer prevention, and cancer control; supportive care; imaging; and health-care systems.

We have also fostered a reputation for hosting events for oncologists, cancer researchers, and policymakers, and convenes many conferences, either independently or in collaboration with partners. Events include branded plenary lectures and sessions at conferences worldwide: Asian Oncology Summit, The Lancet Summit: Cancer care in Asia and Latin America, Oncology At The Limits, Frontiers of Oncology, and Advancing Cancer Immunotherapy, to name just a few.

We publish a range of article types that encompass all aspects of oncological medicine: Articles, Review, Policy Review, Personal View, Clinical Picture, Comment, Correspondence, News, and Perspectives. We also publish Series and Commissions (typically in partnership with societies, governments, NGOs, and academic centres) that aim to shape and drive positive change in clinical practice and health policy in areas of need in global oncology. Learn more about the types of papers we publish.

At UE LifeSciences, we believe that early detection of cancer must be affordable, equitable and accessible to all. We’re an award-winning women’s health company that is developing and scaling innovative solutions to fight common cancers in women globally. Our non-invasive and easy to use hand-held tools enable healthcare providers to bring early detection of breast and cervical cancer to the women in their community, where they live and work. Our innovation has received Innovative Health Technology recognition from the World Health Organization and Global Women’s HealthTech Award from the World Bank in 2022. With headquarters in the United States, UE LifeSciences has presence in India and Malaysia.

The UNICANCER Group brings together the French Comprehensive Cancer Centers (FCCC), promotes their cancer research organisation and pools resources and competencies to give a new dynamic to patient care. Since their creation in 1945, the French Comprehensive Cancer Centers have held a special place in the French health care system. These private, non-profit establishments are entirely devoted to fighting cancer with a view to public service. They have a threefold mission: patient care, research and teaching. UNICANCER builds on the historical community of the FCCC and accentuates what has always been their strength: cooperating and creating synergies between different teams within the network.

Viatris is a global pharmaceutical company, empowering people worldwide to live healthier at every stage of life. Viatris provides access to medicines, advances sustainable operations, develops innovative solutions and leverages collective expertise to connect more people to more products and services through their Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable diseases (NCDs) and infectious diseases, including globally recognized brands, complex generic and branded medicines, a portfolio of biosimilars and a variety of over-the-counter consumer products.  Among NCDs, cancer is one of the leading causes of death worldwide, and the global cancer burden is increasing. Viatris is committed to playing its role in improving access and supporting the UICC global initiative to bridge the gap in cancer care and reduce the burden of cancer globally.

Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Their core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.


World Cancer Research Fund International (WCRF International) leads and unifies a global network of cancer charities dedicated to the prevention and control of cancer by means of healthy food and nutrition, physical activity and weight management. In particular, WCRF International plays a leading role in directing and supporting the research activities of the WCRF global network. Working with researchers, health professionals, policy makers and other health organisations throughout the world, we provide people with the information they need to make choices that can reduce their chances of developing cancer. WCRF's vision is that the their global network helps people make choices that reduce their chances of developing cancer. They were the first cancer charity to create awareness of the relationship between diet and cancer risk, to focus funding on research into diet and cancer prevention and to consolidate and interpret global research to create a practical message on cancer prevention.


American Association for Cancer Research (AACR) · American Society for Clinical Pathology (ASCP) · Chinese Medical Association · European Network of Gynaecological Oncological Trial Groups (ENGOT) · Goodeed · Gryt Health · Iceland Cancer Society · JhPiego · Love, Hope, Strength Foundation  · Princess Margaret Cancer Center · Prostate Cancer Foundation of Australia (PCFA) · Susan G. Komen · Swedish Childhood Cancer Foundation (Barncancerfonden)

Want to join our Champions Programme and play a key role in advancing our global fight against cancer?

For more information, please contact our partnership team at partnerships@uicc.org

Two men shaking hands and smiling

UICC has a long history of uniting with partners to reduce the global cancer burden.

People chatting at the 2018 World Cancer Congress

UICC continues to deliver impact for cancer care through strategic partnerships. Find out how in our Partner related news and blog articles below.

Speakers at 2012 World Cancer Congress Montreal

Becoming a UICC partner is a valuable opportunity for an organisation to expand its global impact on cancer control and to address Sustainable Development Goal 3, to “ensure healthy lives and promote well-being for all at all ages”.

Last update

Monday 08 January 2024

Share this page